IsoPlexis, a US-based proteomics platform developer backed by life sciences and technology group Danaher, has filed on Tuesday to raise up to $100m in an initial public offering.
Founded in 2013, IsoPlexis has developed a single-cell proteomics platform used to study proteins and single-cell biology for the purpose of cancer immunology, cell and gene therapy development.
The company’s products include IsoSpark proteomics instruments ansd IsoCode and CodePlex chip consumables as well as dedicated software. Its revenue grew from $7.5m in 2019 to $10.4m the following year, though its net loss rose to $23.3m in 2020 from $13.6m in 2019.
IsoPlexis completed a $135m series D round in January this year consisting of $85m in equity funding and a $50 million credit facility. It was led by Perceptive Advisors and backed by Ally Bridge Group, funds and accounts managed by BlackRock and undisclosed existing investors.
The company closed its $45m series C round in January 2020 when Northpond Ventures led a $20m extension that included unnamed existing backers. The $25m first tranche was led by Northpond Ventures in May 2019 and included Spring Mountain Capital, Ironwood Capital, North Sound Capital and Connecticut Innovations.
Danaher invested in both the series C and series D rounds, according to the IPO filing. Spring Mountain Capital led IsoPlexis’s $13.5m series B round in 2017, which also drew in capital from Connecticut Innovations, North Sound Ventures and Ironwood Capital.
Regulatory filings show the company had raised at least $9.4m between 2014 and 2016, including a $1.3m round in August 2014 led by Spring Mountain Capital that also featured Yale University, YEI Innovation Fund, Connecticut Innovations and North Sound Ventures.
Shareholders with a stake in IsoPlexis 5% or larger include Danaher, Connecticut Innovations, BlackRock, Northpond Ventures, Perceptive Advisors, Spring Mountain Capital and North Sound Ventures.
IsoPlexis has appointed Morgan Stanley, Cowen, Evercore ISI, and SVB Leerink as underwriters for the offering, which is set to take place on Nasdaq Global Market.